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management of heart failure in 
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whereas in congenital heart disease, this may occur much later 
and may be experienced in adulthood (Table. I).(2) 
Volume overload can be seen in patients born with congenital 
heart lesions with left to right shunting. This dysfunction can 
also be seen in patients with valvular insufficiency. 
Pressure overload is seen in patients with congenital heart 
defects with obstruction to the left ventricular outflow tract.(2) 
These include discrete sub-aortic stenosis, aortic valve stenosis, 
supra-valvular aortic stenosis, aortic arch hypoplasia, aortic 
interruptions of various types and coarctation of the aorta of 
various types.





Causes of ventricular dysfunction are presented in Table I.(2)
Myocarditis may present with acute heart failure and is usually 
caused by a viral insult.(6) It may then progress to chronic heart 
failure in patients that develop dilated cardiomyopathy as a 
complication.
Myocardial ischaemia may be due to anomalous origin of the 
left coronary artery from the pulmonary artery (ALCAPA).(7) 
This may present with heart failure associated with left ventri-
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INTRODUCTION
Heart failure occurs when there is failure of ventricular filling 
associated with a failure to eject blood from the ventricles. 
Heart failure may be due to pump dysfunction, volume overload 
(preload) and pressure overload (afterload).(1) 
Causes of heart failure in children differ to causes seen in 
adults.(2) The most common cause of heart failure in children 
with a structurally normal heart is cardiomyopathy.(3) Most 
studies in the management of heart failure, including clinical 
trials, have been done in adults. Management of children with 
heart failure is therefore based on adult studies.(2) 
EPIDEMIOLOGY
In the United States of America, heart failure accounts for 
14 000 admissions annually, and in-hospital mortality ranges 
between 7 and 11%.(4) The incidence of cardiomyopathy in the 
US is 1.13 cases/100 000 population.(3) The most common 
subtype is dilated cardiomyopathy, followed by hypertrophied 
cardiomyopathy and then restrictive cardiomyopathy. About 
40% of paediatric patients with symptomatic cardiomyopathy 
will be submitted for a cardiac transplant, or succumb within 
the first 2 years of life.(5)  
PATHOPHYSIOLOGY
Heart failure may result from ventricular pump dysfunction, 
volume overload with preserved pump function, and pressure 
overload with preserved pump function.(2) Ventricular pump 
dysfunction may be seen in both acquired and congenital heart 
disease. In acquired heart disease, this occurs early in childhood, 
Heart failure is due to failure of ventricular fi lling with 
failure of ejection of blood from the ventricles. It may 
present as volume overload with ventricular dysfunc-
tion, volume overload with preserved ventricular 
function, and pressure overload. Causes of heart failure 
in the paediatric age group include both congenital 
and acquired heart diseases. Dilated cardiomyopathy 
remains the most common cause of heart failure in the 
paediatric population. In this article, epidemiology; 
pathophysiology; aetiology; clinical presentation; investi-
gations including radiological and laboratory investi-
gations; medical and non-medical management of acute, 
chronic and end-stage heart failure and prognosis will 
be reviewed.   SAHeart 2017;14:6-15
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enough to provide for the body’s needs.(8,9) Atrial arrhythmias, 
like supraventricular tachycardias or junctional or ventricular 
arrhythmias, may cause ventricular dysfunction.(10) 
Toxic drugs may cause ventricular dysfunction or failure. In 
paediatrics, this is often due to chemotherapy, in particular 
anthracyclines.(11) 
Sepsis may cause ventricular dysfunction that results in heart 
failure due to release of cardiotoxic cytokines.(12) 
Complex congenital heart disease may degenerate into 
ventricular dysfunction with heart failure before or following 
surgical intervention, presenting with “burnt-out” myocar-
dium.(13) This may occur quite early or much later in the 
management of these patients with single ventricle aberrations. 
Volume overload
Conditions associated with volume overload and preserved 
ventricular function include ventricular septal defects, patent 
ductus arteriosus, atrioventricular septal defects, aorto-
pulmonary window, single ventricle with unobstructed pul-
monary blood flow and rarely atrial septal defects.(2) Volume 
overload becomes more pronounced in the first 6 - 8 weeks 
after delivery as a result of a physiologic decline in pulmonary 
artery pressures. At this stage, patients may present for the first 
time with heart failure. 
Valve incompetence may lead to volume overload. This would 
include mitral, aortic and pulmonary valve incompetence. 
Pulmonary valve incompetence is usually seen in patients with 
tetralogy of Fallot following repair.(14) 
Pressure overload
Conditions causing ventricular outflow obstruction result in 
pressure overload. It is usually severe outflow obstruction that 
presents with acute heart failure in infancy.
Moderate or severe outflow obstruction may also cause heart 
failure from chronically elevated filling pressures. The obstructive 
lesions associated with heart failure include aortic valve stenosis, 
coarctation of the aorta and pulmonary valve stenosis, amongst 
others.(2) Systemic hyper-tension may also lead to pressure 
overload.(15) 
CLASSIFICATION OF HEART FAILURE
Heart failure can be classified according to its natural progres-
sion or stage following exposure to a risk factor or based on 
severity of clinical progression.(16-21) Heart failure staging in 
infants and children is presented in Table II.(16)
Classification of heart failure severity may include the New York 
Heart Association (NYHA) classification which is applicable 
only to adults and adolescents(17) (Table III); the Ross 
Classification which is applicable to children of all ages and 
cular dysfunction as the pulmonary pressures decrease post-
delivery. 
Arrhythmias
Neonatal complete heart block due to either congenital 
heart disease or maternal autoimmune disease may lead to 
heart failure if the junctional escape rhythm is not adequate 
TABLE 1: Causes of heart failure in infants and children.(2)
Modified from: Hsu DT, Pearson GD. Heart failure in children: Part I: History, etiology, 












• Anomalous left coronary artery arising off the pulmonary artery (ALCAPA)
Arrhythmogenic
• Complete heart block with bradycardia







•  Complex congenital heart defect with concurrent ventricular 
dysfunction
•  Complex congenital heart defect, surgically corrected with late 
ventricular dysfunction (“burnt-out” congenital heart disease)
Preserved ventricular pump function
Volume overload (increased preload)
Left-to-right shunting
• Ventricular septal defect
• Patent ductus arteriosus
• Atrial septal defect (rare)
• Aortopulmonary window
• Atrioventricular septal defect











8based on a history of feeding intolerance, growth problems, 
exercise intolerance and physical signs of heart failure.(18-20) 
Classification of heart failure in the paediatric population may 
also include The New York University Paediatric Heart Failure 
Index.(21) Like the NYHA classification, the Ross classification 
of severity of heart failure in children and infants has 4 classes 
as follows:
Class I:    Asymptomatic.
Class II:    Mild tachypnea or diaphoresis with feeding in infants. 
Dyspnea on exertion in older children.
Class III:   Marked tachypnea or diaphoresis with feeding in 
infants.
     Prolonged feeding times with growth failure.
     Marked dyspnea on exertion in older children.
Class IV:   Symptoms like tachypnea, retractions, grunting, or 
diaphoresis at rest.
Diagnosis
Signs and symptoms of heart failure are a reflection of the 
inability of the heart to produce adequate cardiac output. 
History
Symptoms of heart failure are different at different age groups, 
as follows:(22)
Infants: This age group commonly presents with tachypnea and 
diaphoresis during feeds, decreased amount of feeds, irritability, 
easy fatigability and poor weight gain. 
Young Children: In this group, the symptoms may simulate 
common childhood illnesses like gastroenteritis, reflux, asthma 
or even behavioral problems. These may be abdominal pain, 
nausea, vomiting, poor appetite, failure to thrive, easy fatigability 
and recurrent or chronic cough with wheezing.
Older Children: This age group may present with both cardiac-
specific and cardiac non-specific symptoms such as exercise 
intolerance, anorexia, abdominal pain, wheezing, dyspnea, 
oedema, palpitations, chest pain or syncope. 
Physical examination
The physical findings depend on severity of heart failure and its 
complications like pulmonary congestion.
The clinical signs may include the following:(23) 
 ■ Tachycardia
 ■ Hypotension
 ■ Poor peripheral perfusion due to reduced cardiac output.
 ■ A thrill that may be heard in congenital heart lesions or 
a heave with a displaced apex may be detected in 
cardiomyopathies. 
 ■ Gallop rhythm due to either pump failure, volume overload 
or both.
HEART FAILURE IN INFANTS AND CHILDREN
TABLE 1I: Paediatric heart failure staging and recommended 
therapy.(16)
Modified from: Rosenthal D, Chrisant MR, Edens E, et al. International Society for 
Heart and Lung Transplantation: Practice guidelines for management of heart 
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TABLE III: The New York Heart Association classification of 
heart failure.(17)
Modified from: Hurst JW, Morris DC, Alexander RW. The use of the New York Heart 
Association's classification of cardiovascular disease as part of the patient's complete 






NYHA Functional Classifi cation
Patients with cardiac disease without resulting limitations of 
physical activity.
Patients with cardiac disease resulting in slight limitation of 
physical activity.
Patients with cardiac disease resulting in marked limitation of 
physical activity.
Patients with cardiac disease resulting in inability to carry on 
any physical activity without discomfort.












 ■ Pulmonary oedema, manifesting as respiratory distress and 
other features of respiratory distress like grunting and nasal 
flaring in infants, retractions and use of accessory muscles, 
wheezing or rales (in older children).
 ■ Features of systemic congestion, which include hepa-
tomegaly, jugular venous distension (not generally observed 
in infants and young children) and peripheral oedema. 
 ■ Features suggestive of aetiology of heart failure, which 
include: proximal hypertension in coarctation of the aorta, 
cardiac murmurs seen in congenital heart defects with left 
to right shunting, cardiomyopathies or regurgitant valves. 
INVESTIGATIONS
The diagnosis of heart failure requires radiological and 
laboratory studies. 
Chest Roentgenogram
The chest X-ray assists in the diagnosis of cardiomegaly, 
pulmonary oedema, and in monitoring clinical improvement 
whilst the patient is on heart failure medication.
In left to right shunts, cardiomegaly suggests a moderate to 
large lesion, volume overload with, or without, dysfunction and 
atrial and/or ventricular enlargement. Cardiomegaly may also 
be noted in dilated cardiomyopathy more than myocarditis. 
Right ventricular dilation may be seen in patients with pulmonary 
hypertension and Arrhythmogenic Right Ventricular Hyper-
plasia. Restrictive cardiomyopathy may present with features 
in keeping with bi-atrial enlargement.
Electrocardiogram
The electrocardiogram (ECG) may show sinus tachycardia, a 
feature of heart failure (reduced cardiac output).(24) Varying 
degrees of heart block may be observed in rheumatic heart 
disease, systemic lupus erythematosus and Lyme disease. 
Features of atrial enlargement (restrictive cardiomyopathy) and 
atrial enlargement associated with ventricular enlargement 
can be seen in dilated and hypertrophied cardiomyopathies, 
and in significant left to right shunts. Ventricular enlargement 
may be diagnosed based on QRS Axis deviation together with 
voltage criteria.
Decreased voltage amplitude can be seen in pericardial 
oedema, muscle oedema and some forms of myocarditis. 
T wave changes and ST elevation or depression can be noted 
in various forms of cardiomyopathy and myocarditis.
A deep q wave in inferior and lateral leads (I, aVL, and V5 - V6) 
with ST segment and T wave changes is a classic finding in 
infants with anomalous left coronary arising from the pulmonary 
artery (ALCAPA).(25)
Echocardiography
This is a fundamental diagnostic tool to ascertain whether the 
heart is structurally normal, whether there is a congenital heart 
disease, and whether the heart is enlarged with or without 
ventricular (pump) dysfunction. In a patient with congenital 
heart disease, the echocardiogram may further define cardiac 
anatomy, arterial and venous connections, presence and 
amount of shunting, presence and amount of valvular stenosis 
and regurgitation, atrial and ventricular size, diastolic function, 
estimation of right ventricular and pulmonary artery pressures.
The use of echocardiogram in establishing the cause of heart 
failure and assessing the clinical status of the patient is illustrated 
in the following examples:
 ■ Demonstration of the origin of coronary arteries from the 
aortic root and diagnosis of anomalous origin of the left 
coronary artery from pulmonary artery (ALCAPA).(26) The 
affected infants often have severe left ventricular dysfunction 
and mitral regurgitation at presentation, the latter due to 
papillary muscle infarction. Reversal of colour flow in the 
left coronary artery is highly suggestive of the diagnosis.
 ■ Diagnosis of non-compaction cardiomyopathy, which is a 
rare type of cardiomyopathy, and derives its name from the 
echocardiographic appearance of left ventricular endocardial 
surface which, instead of being smooth, has deep trabe-
culations and multiple deep inter-trabecular recesses 
communicating with the ventricular cavity.(27) 
 ■ In patients with myocarditis and dilated cardiomyopathy, 
echocardiogram may provide accurate assessment of left 
ventricular dilation, mass and function. Left atrial and 
ventricular size may be helpful in determining chronicity, as 
their dilation and ventricular wall-thinning usually suggest 
long-standing dilated cardiomyopathy rather than acute 
myocarditis.(24)
Magnetic resonance imaging (MRI)
The information from echocardiography may be inadequate. 
Cardiac MRI provides accurate and detailed information about 
cardiac anatomy, ventricular function, myocardial inflammation 
(in myocarditis), and infiltration by fat and fibrous tissue.(28-30) 
It is particularly helpful in distinguishing restrictive cardio-
myopathy from constrictive pericarditis. 
Cardiac catheterisation
Cardiac catheterisation may be indicated for haemodynamic 
studies in patients with congenital heart lesions needing surgery, 
or those in need of heart transplant. A combination of cardiac 
catheterisation and myocardial biopsy is the gold standard in 
tissue diagnosis of myocardial disease. Angiography may be 
indicated in the diagnosis of congenital coronary abnormalities. 
Laboratory investigations
Initial laboratory investigations
Complete blood count: The presence of anemia may 
contribute to heart failure in a predisposed patient (e.g. severe 
ventricular septal defect) or exacerbate the severity of failure in 
a patient with preexisting heart failure. In addition, an elevated 
white blood cell count may be indicative of infection, which 
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may also contribute to heart failure or be seen in patients with 
septic shock (who may present with similar symptoms to those 
of patients with heart failure).(24)
Urea and electrolytes: Serum electrolytes, blood urea nitrogen 
and creatinine may be indicated to check for hyponatremia 
which is seen in patients with severe heart failure.(16) Renal 
impairment may be a contributing factor for heart failure or 
may exacerbate preexisting failure.
Baseline electrolytes are needed prior to initiating therapy with 
diuretics or angiotensin-converting enzyme inhibitors to avoid 
potential side effects of these drugs.
Liver function tests: The activity of liver enzymes can be 
elevated due to liver congestion as a result of heart failure.
Additional blood tests
Creatinine kinase and Troponin
These are markers of myocardial injury. Elevated Troponin C 
among children presenting with left ventricular dysfunction 
may suggest acute myocarditis rather than dilated cardio-
myopathy.(31)
Infl ammatory markers
Elevated C-reactive protein and erythrocyte sedimentation 
rate (ESR) may be elevated in myocarditis and may help in 
differentiating this from dilated cardiomyopathy.(24)
Genetic testing
About 30% of cardiomyopathies may be due to a genetic 
cause (especially hypertrophied obstructive cardiomyopathy). 
All patients with cardiomyopathy need a clinical geneticist 
review and directed testing for a genetic cause.(32) 
Brain Natriuretic Peptide (BNP) and N-Terminal pro-
Brain Natriuretic Peptide (NT-proBNP)
BNP and NT-proBNP derive from pro-BNP which is produced 
by the dilated atria.
Whilst BNP and NT-proBNP have been widely studied in 
adults with heart failure, the role of these markers has not been 
elucidated in the paediatric age group. This is due to the fact 
that the paediatric cardiac myocardium reacts differently to 
heart failure compared to the adult myocardium. Also, there 
are no standard norms and values that have been determined 
in paediatrics. 
However, BNP and NT-proBNP levels have been shown:
 ■ to correlate with the presence and amount of shunting 
through a patent ductus arteriosus in premature babies.(33)
 ■ to discriminate serious cardiovascular causes from non-
cardiac causes in newborns admitted with respiratory 
distress to an intensive care unit early after birth.(34)
 ■ to discriminate children with heart failure from those with 
primary pulmonary disease among those presenting with 
respiratory distress.(35)
 ■ to discriminate children with and without a significant 
cardiovascular disease among those referred to a cardi-
ologist.(36)
 ■ to discriminate serious from non-serious disease among 
children with newly diagnosed cardiac disease.(37)
Also, BNP and NT-proBNP levels are higher in children with 
newly diagnosed heart failure or those with acute exacerbations 
of chronic heart failure; higher BNP levels predict poor 
prognosis; improved BNP levels suggest improved ventricular 
function; following complex heart surgery, BNP is predictive 
of heart failure and BNP might be helpful as a marker of 
anthracycline induced myocardial toxicity.(38-43)
Other studies
Anti-streptolysin O-titre and antinuclear antibody are indicated 
for rheumatic fever and lupus. Further investigations may 
include thyroid function tests, carnitine levels and organic 
acids in patients with cardiomyopathy. Blood and Urine studies 




Heart failure is very common, with numerous studies on its 
management including randomised clinical trials performed in 
adults, rather than in children (as mentioned earlier). 
Management of heart failure in children is therefore extrapo-
lated from adult studies. The management plan is directed or 
depends on etiology and stage of heart failure.(16,44) In patients 
with volume overload and preserved ventricular function 
(e.g. large ventricular septal defect, atrioventricular septal defect 
or regurgitant aortic or mitral valves), the management mo-
dality is either cardiac catheterisation or surgical intervention.(44) 
In patients with pressure overload but preserved ventricular 
function (e.g. aortic valve stenosis or hypertrophic cardio-
myopathy), the management approach is cardiac or surgical 
intervention as well. Medical therapy can be given for 
symptomatic relief whilst patients await definitive therapy. In 
patients with ventricular pump dysfunction, with either 
structurally normal hearts or with congenital heart disease, the 
drug choice depends on severity. Diuretics, aldosterone 
antagonists, angiotensin converting enzyme inhibitors (ACEIs), 
angiotensin II receptor blockers (ARBs), digoxin and beta 
blockers (carvedilol) are used routinely in the treatment of 
heart failure in children.(16) In patients with advanced heart 
failure that is refractory to medical therapy, positive pressure 
ventilation, inotropic support, mechanical circulatory support 
and heart transplantation may be indicated. Other therapies 
are directed at reducing risk or to treat complications like 
thromboembolism, arrhythmias and ventricular dyssynchrony. 













TABLE 1V: Diuretic classes, with their mechanisms of action, 






















































































Non-pharmacologic therapy may also include stem cell trans-
plantation, optimisation of nutrition and exercise rehabili-
tation.(16) 
Pharmacologic therapies
Diuretics, digoxin, angiotensin-converting enzyme inhibitors 
(ACEIs), and angiotensin II receptor blockers (ARBs) are 
effective in symptomatic relief of heart failure. Beta-blockers, 
ACEIs, ARBs and mineralocorticoid receptor antagonists 
(MRAs) or aldosterone antagonists have been shown to 
prolong patient survival. ACEIs, ARBs, beta-blockers and 
aldosterone antagonists have been shown to improve left 
ventricular function, reverse left ventricular dilation and 
remodeling. Additional drug therapy for chronic heart failure 
may include Nesiritide, and more novel drugs like angiotensin 
receptor blocker and neprilysin inhibitors (ARNIs) and 
Ivabradine.(45-48) 
Intravenous inotropes and diuretics may be given in patients 
with acute decompensated heart failure or end-stage heart 
failure awaiting heart transplant. 
What’s old?
Diuretics
Diuretics are preload reducers.
They include loop diuretics, thiazides and mineralocorticoid 
receptor antagonists.(49-54) 
Different types of diuretics, their mechanism of action, their 
short and long term effects and their common side effects are 
presented in Table IV. 
In addition, loop diuretics have a shorter duration of action than 
thiazides. Although they act synergistically, combined use of 
these diuretics may potentiate adverse effects.(55)
MRAs also inhibit left ventricular remodeling by inhibiting 
myocardial fibrosis.(54)
Digoxin 
The mechanism of action of digoxin is by inhibiting sodium-
potassium ATPase and increasing intracellular calcium (positive 
inotropic effect). Digoxin slows atrial conduction as well, 
thereby resulting in a negative chronotropic effect.(56) 
It is indicated for treatment of patients with stage C heart 
failure because of its physiologic benefit and symptom relief. It 
is no longer necessary to give high and frequent loading doses 
of digoxin (“digitalising”) as the effects of digoxin are realised 
with smaller doses (through levels on 0.5 - 1ng/mL). Digoxin 
use has not been shown to reduce mortality though.(57) 
Digoxin is not indicated in patients with asymptomatic left 
ventricular dysfunction, as it has not been shown to improve 
morbidity and mortality in such patients. Digoxin has been 
shown not to effect improvement of heart failure in paediatric 
patients with left to right shunts and preserved systolic func-
tion.(50) Common side effects of digoxin include arrhythmias, 
digitalis toxicity, particularly in patients with renal impairment 
or if used with amiodarone.
Angiotensin converting enzyme inhibitors 
Heart failure leads to activation of the renin-angiotensin-
aldosterone system (RAAS) and increased sympathetic tone. 
ACEIs inhibit RAAS by inhibiting the formation of angiotensin II, 
a potent vasoconstrictor that also promotes myocyte 
hypertrophy, fibrosis and aldosterone secretion. Thus, ACEIs 
benefit patients in heart failure first by reducing afterload, 
improving cardiac output and, on chronic use, by mediating 
reversal of left ventricular remodeling.(16) 
ACEIs improve survival and slow progression of heart failure. 
Based on current evidence from adult trials and paediatric 
studies, ACEIs are used in children with ventricular pump 
dysfunction (stage B or C heart failure). Blood pressure and 
renal function should be closely monitored, especially if ACEIs 
are prescribed in neonates.(58)
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Beta blockers
The beta blockers counteract the maladaptive effects of chronic 
sympathetic activation of the myocardium.(59-62) In adults, they 
improve patient survival, reverse left ventricular remodeling and 
decrease myocardial fibrosis. The only trial of beta blockers in 
children showed no benefit of therapy but the trial was 
underpowered and studied a heterogenous population.(80)
They are indicated for use in the treatment of stage C heart 
failure. Beta blockers are usually added to an established 
regimen of diuretics, digoxin and ACEIs. Side effects usually 
include dizziness, fatigue, hypotension, bradycardia, broncho-
spasm and hypoglycemia. 
It is recommended that beta-blockers are discontinued in 
patients with decompensated heart failure (stage D).
Angiotensin II receptor blockers 
The ARBs also inhibit RAAS, like ACEIs, by inhibiting the 
angiotensin II receptor. ARBs are usually reserved for patients 
unable to tolerate ACEIs due to cough or angioedema. There 
is limited use of ARBs in the paediatric age group.
Nesiritide
Nesiritide, which is a recombinant Brain Natriuretic Peptide, 
reduces preload and after load by diuresis, natriuresis, and 
arterial and veno-dilation, suppression of the renin-angiotensin-
aldosterone system (RAAS), thereby improving cardiac 
output without a direct inotropic effect on the myocardium.(45) 
Its mechanism of action is via activation of cyclic Guanalyl 
Monophosphate (c-GMP). The most common side effect is 
hypotension. Nesiritide is not recommended in acute 
decompensated heart failure.
Pulmonary vasodilators
Sildenafil: Sildenafil is a phosphodiesterase type 5 inhibitor.(63) 
Its use in patients with heart failure is associated with improved 
left ventricular function, functional capacity, and quality of life in 
adults with systolic left ventricular dysfunction and secondary 
pulmonary hypertension. 
It has also been shown to improve symptoms of heart failure 
in 13 children with failing Fontan physiology.(64) Sildenafil use in 
the treatment of heart failure with ventricular dysfunction 
remains under investigation. 
Drug therapy for advanced heart failure
Inotropes: Inotropes are used for acute exacerbation of heart 
failure in patients awaiting heart transplant. Their effects are 
mediated through higher intracellular cyclic adenylate mono-
phosphate (cAMP) levels, either by increased production 
(catecholamines) or by decreased degradation (phospho-
diesterase III inhibition).(65,66)
Inotropes in use include milrinone used in combination with 
dobutamine or dopamine.
Milrinone is the preferred choice for inotropic support as it 
improves contractility and reduces after load. It has been given 
on outpatient basis for patients awaiting transplant.(67) 
Non-pharmacologic therapies
Positive pressure ventilation 
Ventilation is indicated for advanced heart failure.(68) Noninvasive 
positive pressure ventilation like continuous positive airway 
pressure or biphasic positive airway pressure assists in reducing 
pulmonary oedema and alveolar recruitment. They also reduce 
left ventricular preload and after load in adults. There are no 
studies in children that have looked at using these modes of 
ventilation in patients with advanced heart failure.
Heart transplantation
This is usually recommended for end-stage heart failure that is 
refractory to medical therapy (stage D).(69) It may be considered 
in patients with less severe heart failure (stage C) if it is asso-
ciated with severe limitation of activity, significant growth failure, 
intractable arrhythmias or restrictive CMO. 
Survival in paediatric heart transplant recipients at 1, 5, and 10 
years after heart transplantation is approximately 90%, 80% and 
60%, respectively.(70)
Early referral to a paediatric heart failure and transplant centre 
should be considered to optimise medical therapy and the 
timing of listing for the heart transplant. 
Decision to pursue transplantation should be based upon the 
expected survival with medical therapy, quality of life, alterna-
tive options for treatment, and estimation of survival post-
transplantation.
Nutrition
Malnutrition is seen in 25% of patients with CMO. Nutritional 
status correlates positively and independently with survival.(71) 
Daily calorie intake of greater than 120kcal/kg for optimal 
growth is recommended, as there are increased metabolic 
demands in patients with heart failure. Salt and fluid intake to be 
discouraged.
Exercise rehabilitation 
Cardiovascular rehabilitation shows promising results. However, 
there is limited data in children.(72)
What’s new?
Angiotensin Receptor blocker and Neprilysin Inhibitors 
(ARNIs)
 LCZ696 is a first-in-class of ARNIs. LCZ696 results in systemic 
exposure to AHU377, a neprilysin inhibitor pro-drug, and 
valsartan, an ARB.(46) AHU377 is then rapidly metabolised by 
non-specific esterases to the active neprilysin inhibitor LBQ657. 
LCZ696 causes dose-dependent increases in ANP, plasma and 
urinary cGMP, plasma renin activity, and angiotensin II, which 













are effects that are consistent with activation of the NPR-A 
receptor and blockade of the angiotensin II type 1 receptor. In 
adult studies, ARNIs have been shown to reduce mortality and 
eliminate side effects associated with ACEIs like angioedema 
and hold much promise for the treatment of chronic heart 
failure.(46,47) There are no published paediatric data available for 
this drug but a study in children is underway. 
Ivabradine
Ivabradine works by selectively blocking the sinus node, thereby 
reducing the heart rate.(48) This has resulted in improved 
morbidity and mortality in patients suffering from chronic heart 
failure. This mode of therapy warrants consideration in 
symptomatic patients (New York Heart Association functional 
class II - IV) in sinus rhythm, with left ventricular ejection fraction 
of ≤35%, and a heart rate ≥70b/min despite optimal treat-
ment with a beta-blocker, ACEI, ARB, and a mineralocorticoid 
receptor antagonist.(73) Ivabradine has been shown to improve 
clinical outcomes and quality of life and to reduce the risk of 
death from heart failure or cardiovascular causes. Ivabradine 
has also been shown to be well tolerated and safe, even at 
maximal recommended doses. At this stage, experience in this 
therapy remains limited to adult patients. 
Mechanical circulatory support
Mechanical circulatory support (MCS) includes extracorporeal 
membrane oxygenation (ECMO) and ventricular assist devices 
(VADs) and may be indicated in patients with decompensated 
heart failure with low cardiac output syndrome that is 
unresponsive to medical therapy.(74) 
It may be used as a bridge to recovery following acute 
decompensation as seen in myocarditis or post-cardiac surgery 
(ECMO), or as a bridge to transplant: (ECMO to VAD). The 
International Society of Heart and Lung Transplant (ISHLT), 
reported that 25% of children received MCS before heart 
transplant. 
ECMO was instituted in patients with post-cardiotomy shock 
following cardiac surgery and acute myocarditis with a 38 - 45% 
survival rate. Mechanical circulatory support should be used as 
long term therapy, particularly in countries where there is no 
heart transplant programme.
Stem cell transplant
Stem cell transplantation is a newer modality of treatment of 
heart failure due to myocardial dysfunction. The therapy has 
been shown to promote cardiac regeneration by potentially 
replacing diseased tissue, enhancing endogenous cellular repair 
and by improving cardiac function.(75) 
The stem cells that have been widely studied are bone marrow-
derived mononuclear stem cells (BMMSCs) and mesenchymal 
stem cells (MMCs).(75) A meta-analysis of 50 Clinical Trials (in 
adults) reported that BMMCs improved left ventricular function 
and survival in recipients. 
In paediatrics, the studies are limited to case series, with mixed 
results. There are no clinical trials reporting use of stem cells in 
children.




In patients with heart failure and moderate ventricular 
dysfunction, Acyl Salicylic Acid (Aspirin) is recommended and 
in children with severe ventricular dysfunction, Warfarin or 
Enoxaparin may be used.(76) In children with restrictive CMO 
with atrial dilation, Aspirin is recommended.
Arrhythmias 
These may present as the underlying cause of ventricular 
dysfunction. Ablation therapy has a role in patients who might 
have chronic atrial tachyarrhythmias.(44) Implantable cardio-
verter defibrillatory (ICD) therapy may be used in a select 
group of patients at risk for sudden cardiac death due to 
ventricular tachycardia (VT) and/or ventricular fibrillation. The 
indications for ICD placement include aborted sudden cardiac 
death, unexplained syncope, and recurrent, sustained VTs.
What’s new?
Ventricular dyssynchrony
Intraventricular conduction delay or left bundle branch block 
(LBBB) may worsen heart failure by causing ventricular 
dyssynchrony. Cardiac resynchronisation therapy (CRT) uses 
biventricular pacing to minimise ventricular dyssynchrony in 
patients with heart failure with prolonged QRS duration 
(LBBB).(77) 
In the paediatric population, there is limited data. One 
retrospective, multicentre analysis of 103 children and young 
adults with congenital heart disease and prolonged QRS 
duration showed that CRT was associated with improvement 
of ventricular ejection fraction from 26 - 40%.(78)
Prognosis 
The outcome in heart failure in children depends on the 
underlying cause, severity or stage of heart failure and whether 
the stage is reversible or not. In the 1980s, 1 year mortality 
rates were 20 - 30%, reaching 40% by 5 years in the first 
world.(79) This has changed due to active transplant program-
mes. Heart transplant remains unavailable in the developing 
countries resulting in high heart failure related mortality. 
Conflict of interest: none declared.
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